Clinical Trial Update: Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating neoadjuvant FOLFIRINOX (FOLF(IRIN)OX) for patients with resectable pancreatic ductal adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• FOLFIRINOX regimen (5-fluorouracil, leucovorin, oxaliplatin, irinotecan)

Snippet

Sponsor: University Hospital, Rouen | Conditions: Resectable Pancreatic Duct Adenocarcinoma | Phase 2 | Status: COMPLETED